With its investment in the fast-growing French genomics expert PathoQuest SAS, SHS is investing in neighbouring France for the first time. PathoQuest is a spin-off of the Institut Pasteur, one of the world’s leading centres for basic research in biology and medicine. PathoQuest plays a leading role in Europe in the field of quality control […]

For almost two years now, the Corona pandemic has had a massive impact on our lives and also on the economy. This is shown by the small dampener of 0.3 percentage points that the SHS Medical Technology Index had to accept in 2020. Compared to the economy as a whole, however, this decline is moderate […]

The Leipzig-based enzyme producer c-LEcta GmbH is one of the fastest growing biotech companies. Among c-LEcta’s customers are manufacturers of corona vaccines as well as the who’s who of global pharmaceutical and food companies. A real success story, to which SHS has also contributed its share. Now SHS has sold its shares in c-LEcta to […]

Since 1993, the Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH has successfully developed and sold more than 68 companies from the medtech industry with capital and know-how. Read three success stories from our contribution to the Voelker brochure “Potentials MedTech 2022”, in which big names in medical technology have their say.

Consistent and reliable: the healthcare sector has been the innovation engine of the German and international economy for years

c-LEcta was able to translate technology leadership into tremendous commercial growth during the holding period of SHS Leipzig-based c-LEcta’s clients include international corporations in the pharmaceutical, chemical and food industries. With the acquisition, Kerry Group intends to further expand the internationalization of the company in the field of enzymes Tübingen / 15.02.2022 The Tübingen-based growth […]

VAMDRUP, Denmark, February 3rd, 2022 – Impilo and SHS have acquired Lowenco A/S (“Lowenco” or the “Company”) from its founder and owners. Lowenco was founded 2013 in Vamdrup, Denmark, and develops, manufactures, markets, and installs large scale modular and highly energy efficient ultra-low temperature (“ULT”) storage solutions for commercial biopharma, primarily targeting the drug substance […]

In January 2021, SHS sold its shares in the Austrian life science supplier Single Use Support GmbH (SUS). The patent-protected liquid logistics system developed by SUS is considered the gold standard today. Among other things, SHS established a scalable corporate organisation at SUS and optimised the supply chains. During the investment phase, SUS multiplied its […]

evitria AG from Switzerland is one of the leading life science companies for specific antibodies. Customers working with evitria products include global pharmaceutical companies as well as academic laboratories and biotech companies around the world. SHS invested from the SHS V fund in 2018. The highly successful exit for SHS investors took place in summer […]

phenox GmbH from Bochum is an extremely innovative, fast-growing medtech company whose products for minimally invasive intervention help prevent or reduce the consequences of a stroke every day. SHS supports the company with growth capital and know-how as it enters new markets.

Private equity: high-yield investment as part of diversification In turbulent times like these, when a lot of money is looking for attractive investment opportunities, private equity is more popular than ever as an investment form among institutional investors. Even in 2020, when the world was hit by the Corona pandemic, there were more than 8000 […]

SHS has been an official member of the United Nations Initiative for Responsible Investment, or UN PRI, since September 2021. What does UN PRI membership mean for SHS? Dr André Zimmermann (Partner and Head of ESG at SHS): As a specialised healthcare investor, SHS has been investing according to ethical standards for more than 25 […]